Metastatic

Type: Keyphrase

Name: Metastatic

First reported 15 hours ago - Updated 1 hour ago - 3 reports

Axitinib in metastatic renal cell carcinoma: Results of a pharmacokinetic and pharmacodynamic analysis - Abstract

Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, approved for second-line therapy for advanced renal cell carcinoma (RCC).Tags:SearchComments (0)Only registered users can write comments!Powered ... [Published UroToday - 1 hour ago]

Entities: Axitinib, renal cell carcinoma, Pharmacokinetics, Metastatic

First reported 5 hours ago - Updated 2 hours ago - 6 reports

Celgene Corporation

Celgene: FDA Gives Priority Review to ...

By Saabira Chaudhuri Celgene Corp. (CELG) said the U.S. Food and Drug Administration has assigned a priority review designation to its supplemental new drug application for Abraxane in combination with gemcitabine for the first-line treatment of patients ... [Published ADVFN UK - 4 hours ago]

Entities: Celgene Corporation, Abraxane, Pancreatic Cancer, FDA Food & Drug Administration, gemcitabine

First reported 4 hours ago - Updated 4 hours ago - 1 reports

Prometheus Laboratories enrolls patients in metastatic melanoma study

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, has announced that PROCLIVITY 01, a multi-center study of Proleukin, or High Dose Interleukin-2, or HD IL-2, plus vemurafenib therapy in patients with BRAF V600 mutation-positive ... [Published Individual.com - 4 hours ago]

Entities: Vemurafenib, IL-2, Skin Cancer, Metastatic

First reported 6 hours ago - Updated 6 hours ago - 1 reports

paclitaxel

An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer

Disclosures: : GlaxoSmithKline (RF); : Esai, GlaxoSmithKline, Sanofi-Aventis (H); , Simon Turner, Steven Stein: GlaxoSmithKline (E, OI). The other authors indicated no financial relationships.Background. Recent data support the hypothesis that combining ... [Published The Oncologist - 6 hours ago]

Entities: Lapatinib, paclitaxel, Herceptin

First reported 16 hours ago - Updated 16 hours ago - 1 reports

ERBB4 confers metastatic capacity in Ewing sarcoma

Metastatic spread is the single‐most powerful predictor of poor outcome in Ewing sarcoma (ES). Therefore targeting pathways that drive metastasis has tremendous potential to reduce the burden of disease in ES. We previously showed that activation of the ... [Published Bionity.com - 16 hours ago]

Entities: Metastatic, sarcoma, Metastasis, Tumor, Cell Lines

First reported 18 hours ago - Updated 18 hours ago - 1 reports

Interleukin-1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features - Abstract

Despite the progress made in the early detection and treatment of prostate adenocarcinoma, the metastatic lesions from this tumor are incurable.Tags:SearchComments (0)Only registered users can write comments!Powered by Compojoom comment 4.2.1Disease ... [Published UroToday - 18 hours ago]

Entities: Prostate Cancer, Metastatic, neuroendocrine

First reported 22 hours ago - Updated 22 hours ago - 1 reports

Recent Research from CHA Stem Cell Institute Highlight Findi. . .

Recent Research from CHA Stem Cell Institute Highlight Findings in General SurgeryGeneral SurgeryNewsRx.comBy a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Researchers detail new data in General Surgery. According to news reporting ... [Published Equities.com - 22 hours ago]

Entities: Metastatic, Stem Cell, General Surgery, Metastasis

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma

Renal cell carcinoma (RCC) is a histopathologically and molecularly heterogeneous disease with the chromophobe subtype (chRCC) accounting for approximately 5% of all cases. 05/22/2013 ... [Published News from Kidney Cancer Association - May 22 2013]

Entities: renal cell carcinoma, temsirolimus, Metastatic

First reported May 22 2013 - Updated May 22 2013 - 6 reports

Oncolytics cancer drug meets mid-stage trial goal, shares rise

May 22 (Reuters) - Oncolytics Biotech Inc said preliminary data from a mid-stage trial showed that its cancer drug, Reolysin, met the main goal of reducing the size of tumors in patients with metastatic melanoma, a type of skin cancer.Shares of the Calgary-based ... [Published Reuters - May 22 2013]

Entities: Oncolytics Biotech Inc, antineoplastic, REOLYSIN, Skin Cancer, Brad Thompson

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer - Abstract

PURPOSE: As part of the ENTHUSE (Endothelin A Use) program, the efficacy and safety of zibotentan (ZD4054), an oral specific endothelin A receptor antagonist, has been investigated in combination with docetaxel in patients with metastatic castration-resistant ... [Published UroToday - May 22 2013]

Entities: docetaxel, Metastatic, Phase III, Patient

First reported May 21 2013 - Updated May 22 2013 - 1 reports

Optimal therapy sequencing in metastatic castration-resistant prostate cancer - Abstract

Prostate cancer is the most common cancer in men worldwide, accounting for approximately 242,000 new cases and 28,000 deaths annually in the USA.Tags:Disease TopicsTopics on Urology Health, Urinary Leakage, Treating Prostate Cancer, Prostate Cancer Diagnosis, ... [Published UroToday - May 21 2013]

Entities: Metastatic, Prostate Cancer, Urology, Bladder Infection

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Androgendeprivation therapy in men with metastatic prostate cancer less may not necessarily be more

More From BioPortfolio on "Androgen-deprivation therapy in men with metastatic prostate cancer: less may not necessarily be more" ... [Published BioPortfolio - May 21 2013]

Entities: Metastatic, Prostate Cancer, BioPortfolio Ltd

Quotes

He adds that there is much work yet to do. "We want to understand the signals that turn TGF-β into a bad guy," he says. "If we know that, we might be able to inhibit those signals, and force damaged cells to die, as they should. That may offer us another treatment possibility, along with TGF-β inhibitors now being tested."

Protein preps cells to survive stress of cancer growth and chemotherapy [Published Medical Xpress - 18 mins ago]

The newly identified compound works by selectively inhibiting a subset of gene-regulating proteins called histone deacetylases (HDACs). "This work supports the need to develop selective HDAC inhibitors for clinical application and, more broadly, illuminates the power of integrating signature-based screening with new approaches to chemical synthesis to provide novel biological insights into human disease" Stegmaier says

New screening approach uncovers potential alternative drug therapies for neuroblastoma [Published PhysOrg.com - 28 mins ago]

"In order to beat your enemy you've got to understand it. We are getting closer and closer to understanding the enemy which is cancer" Hussain adds

Clinical trial tests targeting prostate cancer treatment [Published PR Newswire - 46 mins ago]

...about our broad DCVax technology for personalized immune therapy treatments for all solid tumor cancers," commented Linda Powers, NW Bio CEO. "Immune therapies have become an area of rapidly growing interest among oncologists, and NW Bio is strongly positioned at the forefront of this emerging new treatment category, with two product lines already at the Phase III clinical trial stage and a third product line at the Phase I II trial stage. We look forward to raising awareness of our DCVax technology and products with a major exhibit at this year's ASCO meeting."

NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy fo ... [Published Zecco - 4 hours ago]

More Content

sort by: Date \| Relevance
Protein preps cells to survive stress of cancer... [Published Medical Xpress - 18 mins ago]
New screening approach uncovers potential alter... [Published PhysOrg.com - 28 mins ago]
Clinical trial tests targeting prostate cancer ... [Published PR Newswire - 46 mins ago]
Axitinib in metastatic renal cell carcinoma: Re... [Published UroToday - 1 hour ago]
A case of myocardiac metastasis of clear cell r... [Published UroToday - 1 hour ago]
An evidence-based guide to the selection of seq... [Published UroToday - 2 hours ago]
Mesenchymal Stem Cells as Vectors for Lung Canc... [Published Sexual Development - 2 hours ago]
Quality Gaps and Comparative Effectiveness in L... [Published CHEST - 2 hours ago]
CytRx to Present at the Marcum MicroCap Conference [Published EON: Enhanced Online News - 3 hours ago]
CytRx to Present at the Marcum MicroCap Confere... [Published Yahoo! Finance - 3 hours ago]
CYTRX CORPORATION: CytRx to Present at the Marc... [Published 4 Traders - 3 hours ago]
Celgene: FDA Gives Priority Review to ... [Published ADVFN UK - 4 hours ago]
Celgene: FDA Gives Priority Review to Supplemen... [Published EuroInvestor - 4 hours ago]
NW Bio Exhibit at the Upcoming ASCO Meeting to ... [Published Zecco - 4 hours ago]
CELGENE CORPORATION: Celgene : FDA Gives Priori... [Published 4 Traders - 4 hours ago]
Merrimack Pharmaceuticals Completes Enrollment ... [Published GlobeNewswire: Advertising News - 4 hours ago]
Merrimack Pharmaceuticals Completes Enrollment ... [Published Morningstar.com - 4 hours ago]
Prometheus Laboratories enrolls patients in met... [Published Individual.com - 4 hours ago]
Curis receives approval for basal cell carcinom... [Published Zecco - 4 hours ago]
J&J's Janssen Poised to Continue Driving Growth... [Published Benzinga.com - 4 hours ago]
Celgene Announces FDA Grants Priority Review fo... [Published Benzinga.com - 4 hours ago]
Celgene Announces U.S. FDA Grants Priority Revi... [Published StockHouse USA - 5 hours ago]
Johnson & Johnson Pharmaceuticals Segment Poise... [Published PR Newswire - 5 hours ago]
Johnson & Johnson Pharmaceuticals Segment Poise... [Published FinanzNachrichten.de - 5 hours ago]
Johnson & Johnson Pharmaceuticals Segment Poise... [Published Street Insider - 5 hours ago]
Celgene Announces U.S. FDA Grants Priority Revi... [Published BioPortfolio - 5 hours ago]
OncoGenex Announces Plans for the Initiation of... [Published Yahoo! Canada - 5 hours ago]
An Open-Label Safety Study of Lapatinib Plus Tr... [Published The Oncologist - 6 hours ago]
Predicting Survival in Men with Prostate Cancer [Published Cancernetwork.com - 7 hours ago]
FDA Approves New Drug for Advanced Prostate Cancer [Published AAPS Pharmceutica - 8 hours ago]